Immune Thrombocytopenia in Children: What is the Role of Interleukin-4 and Tumor Necrosis Factor-Alpha?

Samar M. Elfiky1*, Hesham F. Elsayed1, Lyla A. Ezz1, Amany KH. Moustafa1, Nevene R. Wissa2, Amany M. Hassan2

1Department of Pediatrics, Faculty of Medicine, Suez Canal University, Egypt. 2Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Egypt

Abstract

Background: Immune thrombocytopenia (ITP) is a common acquired autoimmune disease in which autoantibody-coated platelets induce phagocytosis by macrophages. Complex immune dysregulation including Th1/Th2 imbalance is involved in the pathogenesis of this disease. Tumor necrosis factor-alpha (TNF-α) and interleukin 4 (IL-4) are cytokines produced by T cells and have various inflammatory, and immunomodulatory activities. Aim: To detect the changes in the level of TNF-α and IL-4 in children with immune thrombocytopenia, and to correlate their levels with the disease course, severity, and response to treatment. Subjects and Methods: This is a case-control study that enrolled 100 subjects divided into 2 groups; patients’ group: children with ITP and age- and gender-matched normal subjects as control. All participants were subjected to complete blood count, assessment of serum TNF-α, and IL-4 using ELISA technique. Results: There was a non-significant difference between patients and control groups (p-value 0.283) in serum IL-4; moreover, there was a non-significant difference in IL-4 levels among different severity grades of ITP. On the other hand, serum TNF-α was significantly higher in the patients’ group than in the control group (p-value 0.002). Both TNF-α and IL-4 levels were significantly higher in newly diagnosed patients. Conclusion: TNF-α levels increase in patients with ITP. TNF-α and IL-4 are significantly higher in patients with newly diagnosed ITP.

Keywords: Immune dysregulation; T Helper cells; ITP; TNF-α; IL-4

Introduction

Immune thrombocytopenia is an immune-mediated acquired disease, characterized by low circulating platelet count caused by the destruction of antibody-sensitized platelets in the reticuloendothelial system(1). The pathophysiology of ITP is heterogeneous and complex. Research advances highlight that complex dysregulation of the immune system is involved in the pathogenesis of this condition(2). This includes an increased number of T
helper 1 (Th1) cells, decreased number or defective suppressive function of regulatory T cells\(^3\), and platelet destruction by cytotoxic T lymphocytes\(^4\). The balance between cytokines leads to regulation of the immune system in normal states and is impaired in many autoimmune diseases. Many studies stressed on the role of serum cytokines in the pathogenesis of ITP and provide evidence to suggest that helper T lymphocytes polarize into Th1 and Th2 immune response\(^1\). The Th1/Th2 balance is important to normal human immunity. Th1 response is characterized primarily by the presence of cytokines IL-2, IFN-\(\gamma\), and TNF-\(\alpha\), whereas the Th2 response produces IL-4, IL-5, IL-6, IL-10, and IL-13\(^5\). IL-4, one of the cytokines secreted by Th2, is a highly pleiotropic cytokine coded by a gene on chromosome 5 that is able to influence T-helper cell differentiation. It participates in the regulation of the immune system at multiple levels. IL-4 is also produced by, basophils, eosinophils, and mastocytes\(^6\). TNF-\(\alpha\), produced by Th1 cells, has a range of inflammatory and immunomodulatory activities\(^7\). It is secreted mainly by macrophages and T cells as a part of host defense against infection and is one of the cytokines that make up the acute phase reaction\(^8\). TNF gene is located on chromosome 6 in class III of the major histocompatibility complex (MHC)\(^9\). Polymorphisms of TNF promoters are associated with high levels of TNF and have been studied as determinants of susceptibility to numerous diseases\(^10\). Previous studies showed significant differences in serum cytokine levels between patients with ITP and healthy controls, indicating that cytokine disturbances might be involved in the pathogenesis of newly diagnosed ITP in both pediatric and adult patients\(^11\). In this study, we investigated two cytokines, TNF-\(\alpha\), produced by Th1 cells and IL-4 produced by Th2 cells among a cohort of Egyptian children with ITP in Suez Canal region and aimed to detect the correlation between their serum levels and both clinical presentation and laboratory data.

**Subjects and Methods**

All participants or their legal representatives provided written informed consent before participating in the study. The Ethics Committee of the Faculty of Medicine, Suez Canal University approved this study. Fifty pediatric patients (age range, 1 to 18 years), as well as 50 apparently healthy (age- and gender-matched) subjects were enrolled in the study and were recruited from the pediatric hematology clinic of Suez Canal University Hospital. All laboratory investigations were performed at the clinical Pathology Department, Suez Canal University Hospital.

**Methods**

All the participants in this study were subjected to complete history taking including disease duration, bleeding manifestations, complications, and family history. A thorough clinical examination was done with special emphasis on the site and shape of bleeding and the presence of organomegaly and lymphadenopathy. ITP is classified into: (1) newly diagnosed ITP: patients within 3 months of diagnosis. (2) Persistent ITP: disease duration between 3 and 12 months of diagnosis. (3) Chronic ITP: if the disease continues for more than 12 months\(^12\). Laboratory investigations were performed in-
Immune Thrombocytopenia in Children

Including complete blood count (CBC) (initially at diagnosis, at discharge, and after 3 months). A peripheral blood smear was examined. Measuring the serum level of tumor necrosis factor – α and IL-4 was done using ELISA technique. Venous samples were collected by standard venipuncture technique. Two ml of blood were collected on an EDTA tube for CBC using Sysmex XN-550.

Thrombocytopenia was divided according to severity to: Mild: platelets count is between 50 and 100 ×10^9/l, moderate: platelets count is between 30 and 50×10^9/l, and severe: platelets count < 30×10^9/l(13). Response to treatment was classified in the studied patients as: (a) Complete response (platelets >100×10^9/l) at least 6 weeks post treatment. (b) Response (platelets between 30×10^9/l and 100) or double the baseline platelets count. (c) No response (platelets count < 30 ×10^9/l or less than double base line platelets count(14). Four mLs of blood were collected on plain tubes for TNF-α and IL-4 assay. Serum samples were stored at -20 °C until assay. Serum TNF-α (Cat. No. E0082Hu) and IL-4 (Cat. No. E0092Hu) ELISA kits were purchased from (Bioassay technology laboratory). The assays were performed according to the manufacturer’s instructions.

Statistical Analysis

Data were analyzed using the statistical package for social sciences (SPSS) for windows version 23.0 (SPSS, Chicago, IL, USA). Descriptive data were presented as mean ± SD or percentages. Fisher's exact test and chi-square test were used for statistical analysis of categorical variables. Because of skewed distributions, analysis of continuous variables was performed by non-parametric Mann-Whitney U-test and Kruskal Wallis test. Multivariate logistic regression analysis was applied to determine predictors for of ITP severity and chronicity.

Results

This case-control study had enrolled children with ITP attending the pediatric hematology clinic, Faculty of Medicine Suez Canal University hospital, Ismailia. Subjects in the control group were 21 females and 29 males; their ages ranged from 1.5 to 17 years old while patients with ITP were 25 males and an equal number of females with ages from 1 to 17 years old (Table 1).

| Variables          | Healthy Controls (n= 50) | ITP patients (n= 50) | p-value |
|--------------------|--------------------------|----------------------|---------|
| Age (yrs.)         | 9.02 ± 3.91              | 6.66 ± 4.76          | 0.139 a |
| mean ± SD          | 10 (1.5 – 17)            | 5 (1 – 17)           |         |
| median (range)     |                          |                      |         |
| Gender, n (%)      |                          |                      | 0.42 b  |
| Male               | 29 (58)                  | 25 (50)              |         |
| Female             | 21 (42)                  | 25 (50)              |         |

a P values are based on as Mann Whitney U test. Statistical significance at P <0.05
b P values are based on as chi-square test. Statistical significance at P <0.05
Table 2 shows the clinical characteristics of the patients’ group. About 44% of the patients had associated anemia and almost all of the patients had bleeding symptoms (92%); of those 43% had Purpura, 24% had gum bleeding, 24% had epistaxis, 4% had bleeding per rectum and finally 2% had menorrhagia (Table 2). The most administered medications were steroids (48%) and Eltrombopag (42%), other less commonly used drugs include IVIG (8%) and Azathioprine (2%). The mean treatment duration in patients with chronic ITP was 9.46±9.41 months, and 72% of the patients showed a positive response to treatment (Table 3). There was a non-significant difference between ITP patients and healthy controls concerning their serum IL-4 (528.96±324.09 and 414.4±197.46 pg/ml) respectively (p=0.283). On the other hand, ITP patients had significantly higher serum TNF-α levels (226.92±179.49 pg/ml) than healthy controls (181.22±160.87 pg/ml) (p=0.002) (Table 4).

Table 2: Clinical characteristics of ITP pediatric patients

| Variables                              | ITP patients (n=50) |
|----------------------------------------|---------------------|
| Age at diagnosis (years)               |                     |
| mean ± SD                              | 4.49 ± 3.87         |
| median (range)                         | 3.4 (0.5 – 13)      |
| Type of ITP: n (%)                     |                     |
| Acute                                  | 28 (56)             |
| Chronic                                | 22 (44)             |
| Severity of ITP: n (%)                 |                     |
| Mild                                   | 4 (8)               |
| Moderate                               | 14 (28)             |
| Severe                                 | 32 (64)             |
| Platelet count (x10⁹/l), (mean ± SD)   | 29.15 ± 26.92       |
| History of anemia: n (%)               |                     |
| Absent                                 | 28 (56)             |
| Present                                | 22 (44)             |
| Severity of anemia (n=22): n (%)       |                     |
| Mild                                   | 15 (68.2)           |
| Moderate                               | 7 (31.8)            |
| Spleen status: n (%)                   |                     |
| Normal                                 | 45 (90)             |
| Splenomegaly                           | 3 (6)               |
| Splenectomy                            | 2 (4)               |
| Bleeding symptoms: n (%)               |                     |
| Absent                                 | 4 (8)               |
| Present                                | 46 (92)             |
| Purpura                                | 43 (86)             |
| Bleeding per gum                       | 12 (24)             |
| Epistaxis                              | 12 (24)             |
| Bleeding per rectum                    | 2 (4)               |
| Menorrhagia                            | 1 (2)               |

We found a statistically significant increase in the level of IL-4 in patients with newly diagnosed ITP (632.86 pg/ml ± 356.61) than in patients with
persistent and chronic forms of the disease (396.73±221.06) (p=0.02). While there was a non-significant difference in the levels of IL-4 among different severity grades of ITP. In addition, there were non-significant relationships between levels of IL-4 and TNF-α and the presence of bleeding symptoms, presence of anemia, or response to treatment. Regarding TNF-α; its levels were significantly higher in patients with newly diagnosed ITP than in persistent and chronic ITP (287.68±191.13), (149.59±130.48) respectively; (p = 0.015). After applying post hoc test TNF-α level was significantly higher in patients with severe disease (271.13±179.53) followed by moderate (175.29±164.01) and then mild disease (54± 59.09) (p=0.013). (Table 5).

### Table 3: Treatment characteristics of ITP in pediatric patients

| Variables                        | ITP patients (n=50) |
|----------------------------------|--------------------|
| Treatment regimen: n (%)         |                    |
| Steroid treatment               | 24 (48)            |
| Eltrombopag                      | 21 (42)            |
| IVIG                             | 4 (8)              |
| Azathioprine                     | 1 (2)              |
| Treatment duration in months     |                    |
| mean ± SD                        | 9.46 ± 9.41        |
| median (range)                   | 7.5 (0.5 – 36)     |
| Response to treatment, n (%)     |                    |
| Absent                           | 14 (28)            |
| Present                          | 36 (72)            |

### Table 4. Comparison of serum IL-4 and TNF-α between ITP pediatric patients and healthy controls

| Variables            | Healthy Controls (n= 50) | ITP patients (n= 50) | p-value |
|----------------------|--------------------------|----------------------|---------|
| IL-4 (pg/ml), Mean ± SD, median (range) | 414.4 ± 197.46, 327.5 (200 – 940) | 528.96 ± 324.09, 422.5 (10 – 1105) | 0.283 a |
| TNF-α (pg/ml), Mean ± SD, median (range) | 181.22 ± 160.87, 99 (18 – 543) | 226.92 ± 179.49, 177 (3 – 543) | 0.002 a |

a P values are based on as Mann Whitney U test. Statistically significance at P < 0.05

Logistic regression analysis was done to determine the predictors of severe ITP and revealed that for every 10 pg/ml increase in the TNF-α level, the odds of having severe ITP increase by 4% (OR=1.004, p=0.025). Male sex was associated with an increase in the odds of having severe ITP 5.7 times compared to females (OR= 5.745, p=0.011) (Table 6). Regarding predictors of ITP chronicity, it was found that the odds of having chronic ITP increase by the decrease in the level of IL-4 and TNF-α serum levels. (OR
=0.997, \( p=0.015 \) (OR=0.995, \( p=0.01 \)) (Table 7).

**Discussion**

Immune thrombocytopenia (ITP) is an autoimmune condition characterized by the presence of isolated thrombocytopenia. ITP is caused by IgG autoantibodies against platelet receptors\(^{(15)}\). In this study, we choose IL-4 and TNF-\( \alpha \) to investigate their effects on ITP manifestations, severity, course, and response to treatment. In the present study, patients with ITP were 25 males and equal number of females with ages ranging from 1 to 17 years old. Although some reports showed that boys and girls are equally affected by childhood ITP\(^{(16,17)}\); other authors found a slight female predominance in ITP patients with a female: male ratio was 1.2/1 in a population-based registration of children with ITP that was performed in Norway\(^{(18)}\). On the other hand, Kuhne et al. found that the male: female ratio was in favor of males (54%) in children aged 2–5 years with female patients being older\(^{(19)}\). While 56% were newly diagnosed. Other reports estimated that the incidence of chronic ITP in childhood was 0.46 per 100,000 children per year with a prevalence of 4.6 per 100,000 children\(^{(18)}\).

**Table 5: Relationship between serum IL-4 and TNF-\( \alpha \) and clinical characteristics of ITP pediatric patients**

| Variables                | Serum IL-4 mean ± SD | \( p \)-value | Serum TNF-\( \alpha \) mean ± SD | \( p \)-value |
|--------------------------|----------------------|---------------|----------------------------------|--------------|
| **Type of ITP**          |                      |               |                                  |              |
| Acute                    | 632.86 ± 356.61      | 0.024         | 287.68 ± 191.13                 | 0.015        |
| Chronic                  | 396.73 ± 221.06      |               | 149.59 ± 130.48                |              |
| **Severity of ITP**      |                      |               |                                  |              |
| Mild                     | 337.5 ± 49.24        | 0.21          | 54 ± 59.09                     |              |
| Moderate                 | 430.21 ± 291.3       |               | 175.29 ± 164.01               |              |
| Severe                   | 596.09 ± 341.21      |               | 271.13 ± 179.5                 | 0.013        |
| **Bleeding symptoms**    |                      |               |                                  |              |
| Absent                   | 379 ± 58.94          | 0.69          | 84.75 ± 68.3                   |              |
| Present                  | 542 ± 334.62         |               | 239.28 ± 181.16               | 0.09         |
| **Anemia**               |                      |               |                                  |              |
| Absent                   | 509 ± 310.11         | 0.58          | 195.86 ± 168.35                |              |
| Present                  | 554.36 ± 336.09      |               | 266.45 ± 189.25               | 0.26         |
| **Response to treatment**|                      |               |                                  |              |
| Absent                   | 583.36 ± 313.76      | 0.43          | 286.71 ± 186.32                |              |
| Present                  | 507.81 ± 329.91      |               | 203.67 ± 173.86               | 0.13         |

\(^a\) \(P\) values are based on as Mann Whitney U test. Statistical significance at \( P<0.05 \)

\(^b\) \(P\) values are based on as Kruskal Wallis test. Statistical significance at \( P<0.05 \)

Edslev et al. found that the platelet count is significantly decreased in both acute and chronic ITP, but it was maximally reduced in patients with acute ITP\(^{(20)}\). In our study, the mean platelet count was 29.15 ± 26.92 (x 10\(^9\)/l). Other studies reported lower platelet counts, Čulić et al., found that at the time of diagnosis, the platelet count was significantly low with (58%) of ITP.
children having a platelet count below $10 \times 10^9/l^{(11)}$. Other authors noted that the mean platelet count was $12.8 \times 10^9/l$ in patients less than 15 years old, and 62% of ITP children had a platelet count of less than $10 \times 10^9/l^{(21)}$. The previously mentioned low platelet count can explain the presence of anemia in 44% of our patients and obviously account for bleeding symptoms in (92%). The bleeding sites vary widely among different authors as we found some reports that 100% of patients had a petechial rash and 91.4% had epistaxis$^{(22)}$. In the current study, there was a non-significant difference between ITP patients and healthy controls concerning their serum IL-4, which was in agreement with another study$^{(23)}$. On the other hand, Talaat and colleagues stated that IL-4 level was significantly higher in ITP patients in comparison with the healthy controls. However, we found that there is a statistically significant increased level of IL-4 in patients with acute ITP than patients with persistent and chronic forms of the disease. Talaat and his colleagues reported similar results of positive correlation between IL-4 and acute ITP$^{(22)}$. Some authors stated that IL-4 is a major role player in autoantibody production and focused on the important role of IL-4 for the differentiation of T-dependent B cells in addition to switching to different IgG isotypes. In addition, the increase in Th2 cytokine (IL-4 and IL-10) levels can affect the differentiation and survival of pathogenic B cells in ITP patients$^{(23)}$. However, we could not find a significant difference in the levels of IL-4 among different severity grades of ITP. In addition, there was a non-significant relationship between levels of IL-4 and the presence of bleeding symptoms, presence of anemia, or response to treatment.

**Table 6. Logistic regression analysis of determinants of severe ITP**

| Predictor              | B    | SE    | OR (95% CI)     | p-value |
|------------------------|------|-------|-----------------|---------|
| Constant               | 0.144| 1.140 | 0.90            |         |
| Age at diagnosis       | -0.175| 0.141 | 0.84 (0.637 – 1.108) | 0.216   |
| Gender                 |      |       |                 |         |
| Male vs. female (R)    | 1.748| 0.690 | 5.745 (1.486 – 22.19) | 0.011*  |
| serum α-TNF            | 0.004| 0.002 | 1.004 (1.001 – 1.008) | 0.025*  |

*CI; Confidence interval, a Statistical significance at p < 0.05

**Table 7: Logistic regression analysis of determinants of chronic ITP**

| Predictor              | B    | SE    | OR (95% CI)     | p-value |
|------------------------|------|-------|-----------------|---------|
| Constant               | -0.244| 0.953 | 0.798           |         |
| Age at diagnosis       | 0.403| 0.231 | 1.496 (0.952 – 2.352) | 0.081   |
| Gender                 |      |       |                 |         |
| Male vs. female (R)    | -0.566| 0.836 | 0.568 (0.11 – 2.923) | 0.498   |
| Serum IL-4             | -0.003| 0.001 | 0.997 (0.995 – 0.999) | 0.015*  |
| Serum α-TNF            | -0.005| 0.002 | 0.995 (0.991 – 0.99) | 0.01*   |

* CI; Confidence interval, a Statistical significance at P < 0.05

Regarding TNF-α, ITP patients had significantly higher serum TNF-α levels than healthy controls, and its levels were significantly higher in patients
with acute than chronic ITP. This was in agreement with Talaat and co-authors who found that TNF-α has a positive correlation with acute ITP, and he also found that TNF-α levels are significantly elevated in patients with ITP compared to healthy controls\(^{(22)}\). These results are in line with 2 other studies that confirmed that increased levels of TNF-α in patients with ITP lead to macrophage activation, which is stimulated by autoantigens against platelets and results in T cell activation, then, activation of B cells. Moreover, The Th1/Th2 balance was found to be disturbed in patients with ITP, as the cytokines produced by Th1 (IFN-γ, TNF-α and IL-2) have a role in the cell-mediated inflammatory reaction, delayed hypersensitivity, and cytotoxic reaction activation, while Th2 cytokines (IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13) lead to excess antibody production\(^{(24,25)}\). The above-mentioned data can explain the results of logistic regression analysis that was done to detect the predictors of ITP severity and chronicity and revealed that the increase in the TNF-α level will increase the odds of diagnosing severe ITP; we also found that male sex was associated with increased risk of severe ITP. On the other hand, decreased level of both IL-4 and TNF-α was significantly associated with an increased risk of chronic ITP.

**Conclusion**

TNF-α level increases in patients with ITP. TNF-α and IL-4 are significantly higher in patients with newly diagnosed ITP. A high level of TNF-α can predict severe ITP at diagnosis, while a decrease in the level of both IL-4 and α-TNF can predict chronic ITP.

**Acknowledgment:** We would like to thank our colleagues from Pediatrics, and Clinical Pathology departments.

**Financial Support:** None

**Conflicts of interest:** None

**References**

1. Neunert C, Lim W, Crowther M, et al. American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190-207.
2. Sandler SG. The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura. Semin Hematol 2000; 37:10.
3. Panitsas FP, Theodoropoulou M, Koutraklis A, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of type -1 polarized immune response. Blood 2004; 103(7):2645-2647.
4. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008; 15;112(4):1325-8.
5. Wang T, Zhao H, Ren H, Guo J, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005; 90(7):914-23.
6. Wu M-C, Huang C-M, Tsai JJ, et al. Polymorphisms of the interleukin-4 gene in Chinese patients with systemic lupus erythematosus in Taiwan. Lupus 2003;12(1):21-25.
7. Hajeer AH, Hutchinson IV. Influence of TNF alpha gene polymorphism on TNF alpha production and disease. Hum Immunol 2001; 62(11): 1191-1199.
8. El Sissy MH, El Sisy AH, Elanwary S. Tumor necrosis factor alpha -308G/A gene polymorphism in Egyptian children with immune thrombocytopenic purpura. Blood Coagul Fibrinolysis 2014; 25(5): 458-463.
9. Qidwai T & Khan F. Tumor necrosis factor gene polymorphism and disease prevalence. Scand J Immunol 2011; 74(6): 522-547.
10. Batikhan H, Gokcan MK, Beder E, et al. Association of TNF alpha -308 G/A polymorphism with nasal polypsis. Eur Arch Otorhinolaryngol 2010; 276(6): 903-908.
11. Ćulić S, Salamunić I, Konjevoda P, et al. Immune thrombocytopenia: serum cytokine levels in children and adults. Med Sci Monit: International Medical Journal of Experimental and Clinical Research. 2013;19:797.
12. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood adv 2019 Dec 10;3(23):3829-66.
13. Schlappi C, Kulkarni V, Palabindela P, et al. Outcomes in Mild to Moderate Isolated Thrombocytopenia. Pediatrics. 2018; 142(1):e20173804.
14. Neunert CE. Current management of immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2013; 2013:276-82.
15. Adams G, Graebner L, Sayed A, et al. Cytokine fluctuations in immune thrombocytopenia (ITP) over time; insights into the pathogenesis and evolution of the disease. Blood. 2016 Jan 1;128(1):2549.
16. Abrahamson PE, Hall SA, Feudjo-Tepie M, et al. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol 2009; 83(2):83-9.
17. Donato H, Picón A, Martinez M, et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer 2009; 52(4):491-6.
18. Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr. 2005 Feb;94(2):178-84.
19. Kühne T, Berchtold W, Michaels LA, et al. Intercontinental Cooperative ITP Study Group. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica. 2011; 96(12):1831-7.
20. Edslev PW, Rosthøj S, Treutiger I, et al. A clinical score predicting a brief and uneventful course of newly diagnosed idiopathic thrombocytopenic purpura in children. Br J Haematol 2007; 138(4):513-6.
21. Kurata Y, Fujimura K, Kuwana M, et al. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011 Mar;93(3):329-35.
22. Talaat RM, Elmaghraby AM, Barakat SS, et al. Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP). Clin Exp Immunol. 2014 May;176(2):291-300.
23. Webber NP, Mascarenhas JO, Crow MK, et al. Functional properties of lymphocytes in idiopathic thrombocytopenic purpura. Hum Immunol. 2001 Dec 1;62(12):1346-55.
24. La Cava A. Tregs are regulated by cytokines: implications for autoimmunity. Autoimmun Rev. 2008 Oct 1;8(1): 83-7.
25. Malinowska I, Obitko-Pludowska A, Buescher ES, et al. Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura. Hematol. J. 2001 Jan 1;2(4):242-9.